Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Vero/hSLAM Cells for Isolation of Measles Virus


The availability of a sensitive cell line for isolation of measles virus from clinical specimens and establishment of RT-PCR and automated DNA sequencing techniques have allowed for rapid genetic characterization of a large number of wild-type strains of measles virus. A database of sequence information now makes it possible to use molecular epidemiological techniques to identify the source of wild-type viruses and to differentiate between wild type and vaccine strains.

The Vero/hSLAM cell line [hSLAM=(human) signaling lymphocytic activation molecule] is recommended for use in the laboratories that provide measles surveillance as part of the World Health Organization's Measles and Rubella Laboratory Network (WHO LabNet) [1]. The Vero/hSLAM cells are Vero cells that have been stably transfected with a plasmid encoding the gene for the human (h) SLAM molecule [2]. SLAM has been shown to be a receptor for both wild-type and laboratory-adapted strains of measles. The sensitivity of Vero/hSLAM cells for isolation of measles virus is equivalent to that of B95a cells. The advantage to the Vero/hSLAM cells is that, unlike the B95a cells, they are not persistently infected with virus. This provides a significant safety advantage for laboratorians and greatly facilitates international shipments. The disadvantage of the Vero/hSLAM cells is that they must be cultured in medium containing geneticin to retain SLAM expression. This increases the cost of the tissue culture medium. Protocols for culture of Vero/hSLAM cell are included at the end of this section.

measles in vero-slam

Figure (above) shows CPE from wild-type measles virus in Vero/hSLAM cells (photo on right). Picture was taken 48 hours after inoculation. Uninfected Vero/hSLAM cells are shown in the photo on the left.

Vero/hSLAM cells were developed by Dr. Yusuke Yanagi, Kyushu University, Kukuyoka, Japan. He has kindly agreed to allow the WHO LabNet to use these cells under the following conditions:

  1. The cell line Vero/hSLAM is used only for laboratory diagnosis of measles and rubella viral infection by virus isolation and/or investigation of measles or rubella strains for molecular epidemiological purposes.
  2. The cell line is not used for commercial purposes.
  3. The cell line is not distributed to laboratories outside the WHO LabNet without Dr. Yanagi's and WHO's permission.
  4. Any publication of work using the Vero/hSLAM cell line acknowledges the original publication (Ono et al. J. Virol. 2001;75:4399-4401).
 Top of Page

Vero/hSLAM Cells: Overview

LabNet laboratories should only accept Vero/hSLAM cells from a WHO-approved source (Regional Reference Lab or Global Specialized Lab). Upon receipt, the cells should be passaged in medium containing 400 ug/ml geneticin as described below. Laboratories should passage the cells 2 to 4 times in the presence of geneticin to prepare a sufficient number of cell culture vessels to prepare 20-50 vials for liquid nitrogen storage.

Note: Passage of Vero/hSLAM cells for routine virus isolation: To prepare cells for virus isolation procedures, Vero/hSLAM cells can be recovered from liquid nitrogen and passaged up to 15 times in medium without geneticin. These cells should be used for virus isolation attempts only and should be discarded after 15 passages. Even with addition of geneticin to the medium, the cells should not be passaged forward beyond about 20-30 passages, as with the standard Vero cell line. Cells that have been passaged without geneticin in the medium should never be used to prepare cell stocks for liquid nitrogen storage or shipped to another network laboratory for use in virus isolation.



  1. Dulbecco’s Modified Eagle Medium (DMEM):

    with 4,500 mg/L D-glucose (high glucose)
    with L-glutamine
    without sodium pyruvate

  2. Antibiotics (100X)

    10,000 units/ml penicillin G
    10,000 ug/ml streptomycin sulfate
    both in 0.85% saline

  3. Trypsin-EDTA

    0.05% Trypsin (porcine pancreas)
    0.53 mM EDTA
    in HBSS without Ca++ and Mg++

  4. Fetal Bovine Serum (Defined)
  5. Geneticin (G418), is available in solution (50 mg/ml) or powder.
  6. Dimethyl Sulfoxide (DMSO)
 Top of Page


  1. Prepare DMEM by adding appropriate amount of penicillin/streptomycin solution for final 1X concentration and geneticin (G) to a final concentration of 400 ug/ml of DMEM. (If using the geneticin solution prepared as 50mg/ml, 1 ml is added to 125 ml of medium.) Use this medium (DMEM + G) for expanding culture for freezer stocks of Vero/hSLAM cells.
  2. When confluent, Vero/hSLAM cells can be passaged by trypsinization as with any adherent cell line. We usually maintain cells in 75 cm 2 flasks, but volumes can be adjusted for larger or smaller vessels.
  3. Wash cell monolayer 1 time with 3-5 ml pre-warmed trypsin solution (or warm PBS) for about 30 seconds to 1 minute. Discard wash medium. Add 5 ml pre-warmed trypsin solution and place flask in 37°C incubator. Observe flask every few minutes and to see if cells have begun to detach.
  4. Resuspend cells in 5 ml DMEM (see note regarding addition of geneticin above) plus 10% FBS and pipette up and down to break up clumps. Seed cells into flasks containing DMEM plus 10% FBS. Split ratios of up to 1:5 are acceptable. A 1:2 or 1:3 split usually will produce monolayers of sufficient density for virus isolation after 24 hours incubation.
  5. For inoculations, virus adsorption and subsequent incubations should be in DMEM plus 2% FBS. For inoculation of a 25 cm2 flask, (virus passage #1), decant growth medium, add 5 ml of DMEM plus 2% FBS and 0.5-1 ml of specimen. Incubate at 37°C for 1 hour and observe the cells under the microscope to ascertain if the sample was toxic to the cells (rounding of cells, cells floating).
  6. Inoculated cells should be observed for cytopathic effect (CPE) on a daily basis. Passage the infected Vero/hSLAM cells by trypsinization every 4-5 days at a 1:2 or 1:3 split ratios. When CPE is visible, continue to feed the cells (replace the medium with fresh DMEM with 2% FBS, if necessary) until the CPE becomes extensive. It may be necessary to passage the cells 1-2 times to allow the infection to spread before cells become overgrown. When CPE is visible over at least 50-75% of the cell layer, the virus has reached a suitable titer for viral stock.
  7. To prepare a viral stock, scrape the cells into the medium with a cell scraper. Mix and distribute to 4-6 vials. Always prepare viral stocks if isolation is successful.
 Top of Page

Preparation of Stock (Frozen) Vero/hSLAM Cells

It is important to prepare multiple frozen stock vials of Vero/hSLAM cells. Upon receipt of the cell line, the cells should be passaged for preparation of the stock vials. Cells can be frozen using any standard cryopreservation technique. Commercial freezing media is available or the reagents described below should be adequate.

Cells should be removed from the flask by trypsinization (take care not to over-trypsinize). All of the cells from a 150 cm2 flask should be placed in 10 ml DMEM plus 10% FBS and pelleted by centrifugation at 1500 rpm for 10 min at 4°C. Add 5 ml DMEM containing 30% FBS to the cell pellet and resuspend the cells by gentle vortexing. Add an equal volume (5 ml) of DMEM and 15% DMSO (reagent grade). Pipette gently up and down briefly and dispense 1 ml into 10 plastic cryovials. The vials should be cooled slowly using a programmed cell freezer or a commercial product designed for gradual temperature reduction. Store vials in liquid nitrogen.


Use of trade names or commercial sources is for identification only and does not imply endorsement by CDC.



  1. Featherstone DA, Rota PA, Icenogle J, Mulders MN, Jee Y, Ahmed H et al. Expansion of the global measles and rubella laboratory network 2005-09. J Infect Dis. 2011:204(Suppl 1);S491-S498.
  2. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y et al. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol. 2001:75;4399-4401.
 Top of Page